• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » ‘Life Science Panorama 2011’ report looks at France

‘Life Science Panorama 2011’ report looks at France

May 23, 2012
CenterWatch Staff

France Biotech, the French association of life science companies, in partnership with Ernst & Young, published the 10th annual “Life Science Panorama,” describing the industry's main trends for 2010-2011 in France and worldwide.

Almost 200 French companies took part in this year’s survey. The panorama highlights the maturity threshold attained by the life science industry, equivalent to that of the pharmaceutical industry thanks to a wide variety of highly sought-after products. It also focuses on the first acquisitions of foreign companies by French companies and the first takeovers of listed French companies.

“In spite of the difficult period we are going through, our sector is proving its vitality. Its turnover is continuing to increase significantly and it is entering into partnerships with high potential,” said André Choulika, chairman, France Biotech.

In the report, France ranked second in the world in terms of number of life science companies, with a total of 1,359 throughout France. These companies are mainly located in the Ile de France region (33% as in 2010), the Rhône-Alpes region (15% as against 16.6% in 2010) and the PACA (Provence-Alpes-Côte d'Azur) region (8.2% as against 10.5% in 2010). It should be noted that 6% of these companies are in the Midi-Pyrénées region and 6.6% (4.9% in 2010) in the Loire region, a trend boosted by the centre of competitive excellence. Nearly half (48.5%) of the French companies are from the academic sector.

Over the past few years, biotechnology companies have become the main potential for growth for France’s pharmaceutical industry, now the largest client of innovative companies (33%), along with public research laboratories. Eighty-five partnerships were entered into in 2011. Biotechnology companies often stem from an academic discovery and then remain closely affiliated with their laboratory of origin. The percentage of partnerships stemming from academic research rose from 49% in 2010 to 52% in 2010, showing an increase in this field.

The report found the financing of French biotechnology companies (via venture capital, IPOs or refinancing on the financial markets) dropped sharply between 2010 and 2011, falling by 40% from $582 million to $350 million. This trend could also be observed in the biotech sector in all of Europe, where financing fell by 36%.

In parallel, the companies questioned continue to overwhelmingly favor the various tools made available to the public authorities (Oséo, the French state innovation agency, and C.I.R., tax rebates for research), while underlining, however, the extremely negative impact of the reform of the Young Innovative Company status.

“The innovation grant reforms [have] blocked the path of many of our fast-developing companies, and may continue to do so,” said André Choulika, chairman, France Biotech. “France Biotech will continue battling to get the government to review its standpoint on the recent reforms and will remain vigilant as regards future reforms.”

Franck Sebag, a partner at Ernst & Young, concluded, “As financial resources continue to dry up, companies in the sector will have to develop more rapidly. Therefore, concentration phenomena could increase, or we may be faced with the development of the 'open innovation' phenomenon.”

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing